Centogene Regains Compliance With Nasdaq Listing Requirement
In December, the company was notified that its shares had failed to meet the Nasdaq's minimum bid price listing requirement.
LumiraDx Receives Notice From Nasdaq Over Missed Listing Requirement
The UK-based point-of-care diagnostics company received the letter because its common shares on the Nasdaq closed below $1 for 30 consecutive trading days.
Centogene Gets Nasdaq Non-Compliance Notice
The company has 180 days from the date of the notice to regain compliance with the listing requirement, during which time it will continue to trade on the exchange.
T2 Biosystems Regains Compliance with Nasdaq Listing Requirement
The company had previously been informed that its shares failed to meet the exchange's $1 minimum bid price requirement.
DiaCarta to go Public Through SPAC Merger
The firm would join a number of biopharma and diagnostic companies that have used SPACs during the COVID-19 pandemic to tap the public markets.